On November 25, the medical journal “The Lancet Diabetes and Endocrinology” published the latest research report stating that researchers conducted large-scale clinical trials on 7 drugs containing GLP-1 agonists, including simeglutide, duraglutide, and liraglutide. The analysis results showed that compared with placebo, GLP-1 receptor agonists reduced the risk of kidney failure by 16%, and the risk of worsening kidney function by 22%.

Zhitongcaijing · 11/26 11:17
On November 25, the medical journal “The Lancet Diabetes and Endocrinology” published the latest research report stating that researchers conducted large-scale clinical trials on 7 drugs containing GLP-1 agonists, including simeglutide, duraglutide, and liraglutide. The analysis results showed that compared with placebo, GLP-1 receptor agonists reduced the risk of kidney failure by 16%, and the risk of worsening kidney function by 22%.